what is PID in bioreactor how to calculate

PID (Proportional-Integral-Derivative) control is a control loop feedback mechanism used to regulate the temperature, pH, and other process variables in a bioreactor. It is commonly used in the control systems of bioreactors to maintain a steady state and avoid large fluctuations in the process variables.

The PID controller calculates the error between the desired set point and the current process variable and then generates a correction signal to adjust the process. The correction signal is generated by combining three control terms:

Proportional control: This term generates a correction signal that is proportional to the error between the set point and the current process variable. The proportionality constant is known as the proportional gain (Kp).

Integral control: This term generates a correction signal that is proportional to the integral of the error over time. The integral gain (Ki) is used to adjust this term.

Derivative control: This term generates a correction signal that is proportional to the derivative of the error over time. The derivative gain (Kd) is used to adjust this term.

The PID controller uses these three control terms to calculate the overall correction signal. The correction signal is then used to adjust the process by changing the flow rate of the coolant, the agitation rate, or other process variables.

To calculate the PID gains, there are several methods such as Ziegler-Nichols, Cohen-Coon, Tyreus-Luyben, and so on. These methods can be used to determine the optimal values of the proportional, integral, and derivative gains for a specific process. Once the PID gains are calculated, the controller can be tuned to achieve the desired performance.

It is worth noting that the choice of the optimal values of PID gains depends on the process and the desired performance, so it's important to use a systematic approach when tuning the controller to achieve the best results.

Comments

Post a Comment

Popular posts from this blog

article review on tocilizumab production

Tocilizumab (Actemra) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which is involved in the inflammatory response. It is used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis and other inflammatory conditions. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. One research article "Development of an efficient and scalable fed-batch culture process for the production of tocilizumab in Chinese hamster ovary cells" by Li et al. (2019) aimed to optimize the production of tocilizumab using a fed-batch cultivation system in CHO cells. The study aimed to improve the yield and quality of the protein, and to develop a process that can be easily scaled up for industrial production. The results of the study showed that the yield of tocilizumab was significantly improved by optimizing the culture conditions, such as the temperature, pH, and dissolved oxygen, as well as by using a specific
Read more

MOA OF AMINOGLYCOSIDE ANTIBIOTICS

Image
MOA                  of   Aminoglycoside             Antibiotics Aminoglycosides exert their bactericidal effect by inhibiting protein synthesis in bacteria and compromising the structure of the bacterial cell wall . Aminoglycoside Antibiotics Aminoglycoside antibiotics are used to treat serious infections caused by gram-negative bacteria . Some commonly used aminoglycosides include: amikacin (Amikin®); apramycin; capreomycin; gentamicin (Garamycin®); kanamycin (Kantrex®); neomycin (Mycifradin®); netilmicin (Netromycin®); paromomycin (Humatin®); streptomycin; tobramycin (TOBI Solution®, TobraDex®, Nebcin®) Mode of Action Although aminoglycosides stop bacteria from making proteins, it is uncertain whether this is the action that results in bacterial cell death.     Disruption of Protein Synthesis A minoglyco s i d e s b i n d to the b a c t er i al 3 0 S r i b o s o mal s ubunit. R i b o s om e s are the p ro t e i n
Read more

article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein. The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of th
Read more